Home » Topics » Regulatory » EMA

EMA
RSS

EMA accepts ospemifene MAA

March 28, 2013

European CHMP recommends restriction on use of cilostazol-based medicines

March 26, 2013

CHMP recommends against E.U. approval of Gentium's defibrotide

March 26, 2013

CHMP recommends approval of rivaroxaban in new indication

March 26, 2013

FDA and EMA set to review Piramal Imaging's marketing applications

March 26, 2013

CHMP recommends European approval of Biogen Idec's Tecfidera

March 25, 2013

EMA committee recommends approval of ponatinib for two cancer indications

March 25, 2013

European CHMP recommends approval of Aubagio for relapsing-remitting MS

March 25, 2013

Stribild gets positive opinion in Europe

March 25, 2013

CHMP issues positive opinion on HyQvia

March 25, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...